إعلان
إعلان

RCEL

RCEL logo

Avita Medical, Inc. Common Stock

3.31
USD
برعاية
-0.11
-3.36%
٠٧ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

3.30

-0.01
-0.15%

تقارير أرباح RCEL

النسبة الإيجابية المفاجئة

RCEL تفوق 7 من 15 آخر التقديرات.

47%

التقرير التالي

بيانات التقرير القادم
١١ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$17.82M
/
-$0.34
التغير الضمني من Q3 25 (Revenue/ EPS)
+4.43%
/
-26.09%
التغير الضمني من Q4 24 (Revenue/ EPS)
-3.20%
/
-22.73%

Avita Medical, Inc. Common Stock earnings per share and revenue

On ٠٦ نوفمبر ٢٠٢٥, RCEL reported earnings of -0.46 USD per share (EPS) for Q3 25, missing the estimate of -0.28 USD, resulting in a -58.78% surprise. Revenue reached 17.06 مليون, compared to an expected 18.55 مليون, with a -8.00% difference. The market reacted with a +10.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 المحللين forecast an EPS of -0.34 USD, with revenue projected to reach 17.82 مليون USD, implying an نقصان of -26.09% EPS, and زيادة of 4.43% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Avita Medical, Inc. Common Stock reported EPS of -$0.46, missing estimates by -58.78%, and revenue of $17.06M, -8% below expectations.
The stock price moved up 10.88%, changed from $3.40 before the earnings release to $3.77 the day after.
The next earning report is scheduled for ١١ فبراير ٢٠٢٦.
Based on 7 المحللين, Avita Medical, Inc. Common Stock is expected to report EPS of -$0.34 and revenue of $17.82M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان